Imagine you need a specific medicine—say, insulin for diabetes—but the only way to get it used to be from the pancreas of cows or pigs. That was expensive, risky (animal proteins could trigger allergies), and never quite identical to human insulin. Now, we can take the human gene that makes insulin, put it into a harmless bacterium or yeast, and let that microbe churn out perfect human insulin in huge vats. That is the core idea of recombinant protein therapeutics.
Recombinant means "made by combining DNA from different sources." Protein therapeutics means "a protein used as a medicine." So, recombinant protein therapeutics are medicines that are proteins, made by genetically engineered living cells, to treat or prevent disease.
The NCERT textbook (Class 12 Biology, Chapter 12, Biotechnology and its Applications) introduces this under "Biotechnological Applications in Medicine." It specifically mentions human insulin (Humulin) as the first recombinant therapeutic approved for human use. The textbook explains that the human insulin gene was inserted into E. coli bacteria, which then produced insulin identical to our own.
How does it work, step by step?
- Identify the gene that codes for the therapeutic protein (e.g., the gene for human insulin, growth hormone, or clotting factor).
- Insert that gene into a "vector" (a carrier DNA, often a plasmid from a bacterium) using restriction enzymes and DNA ligase.
- Introduce the vector into a host cell (usually E. coli bacteria, yeast, or mammalian cells). This host cell is now "transformed" – it carries the human gene.
- Grow the host cells in large fermenters. As they multiply, they follow the human gene's instructions and produce the human protein.
- Purify the protein from the culture. The final product is a pure, human-identical therapeutic protein, free from animal contaminants.
Why does this matter? (The "why" for a commerce/humanities student)
- Safety and Efficacy: Because the protein is exactly human, the body rarely rejects it. No risk of animal viruses or allergic reactions to animal proteins.
- Scalability: You can produce massive quantities in a lab, independent of animal supply. One batch of engineered bacteria can make more insulin in a day than thousands of pig pancreases.
- Cost (eventually): While initial R&D is expensive, mass production drives down cost, making life-saving drugs accessible to more people.
- New Treatments: It enables therapies that were impossible before—like monoclonal antibodies for cancer, or erythropoietin for anaemia in kidney patients.
The NCERT textbook emphasises that recombinant therapeutics are "relatively free from risk of infection and immune response" compared to products extracted from animals or human cadavers. This is the single biggest advantage: purity and human compatibility.
Examples you should know (from NCERT and common knowledge) …